Saposin B Deficiency

Mutations in the PSAP gene have been associated with prosaposin deficiency, Krabbe disease, metachromatic leukodystrophy and Gaucher disease. There have been only a few reports of patients with prosaposin deficiency all of whom were described as having a severe neurovisceral storage disease that was evident at birth with a rapidly fatal course. Hypotonia, hepatosplenomegaly, myoclonic jerks, abnormal ocular movements, dystonia and seizures were also described. At this time, only a single patient has been described with Krabbe disease due to saposin A deficiency. This patient had dysmyelination of the cerebral white matter with a very rapid neurological deterioration that ended in death at eight months. Most patients with metachromatic leukodystrophy due to saposin B deficiency have presented with the late infantile form in which symptoms appear between the ages of 1 to 2 years with neuroregression, walking difficulties, dysarthria and lower limb spacticity. Patients with the juvenile-onset and adult-onset forms have also been described. In Saudi Arabia metachromatic leukodystrophy due to saposin B deficiency appears to be more common than the classic arylsulfatase A-deficient metachromatic leukodystrophy. The majority of patients with Gaucher disease due to saposin C deficiency have most often been described as having type 3 (subacute or chronic neuronopathic) Gaucher disease that is characterized by severe systemic involvement and supranuclear saccadic horizontal gaze palsy, with our without developmental delay, hearing impairment and other brainstem deficits, or a relatively mild systemic disease but with progressive myoclonic encephalopathy, seizures, dementia and death. However, patients with saposin C deficiency who have the more common type 1 Gaucher disease presentation have also been reported.

Tests Available

Forms and Documents

Test Details

  • Confirmation of biochemical diagnosis
  • Testing of patients with the phenotype of metachromatic leukodystrophy, Gaucher disease or Krabbe disease without the characteristic in vitro enzyme deficiency.
  • Carrier testing
  • Prenatal diagnosis in at risk pregnancies


4 weeks
2-5 mL Blood - Lavender Top Tube
Buccal Swabs

*Reporting times are typical, but could be extended in situations outside GeneDx's reasonable control.


  • 330.2 Cerebral degeneration in generalized lipidoses; Code first underlying disease, as: Fabry's disease (272.7), Gaucher's disease (272.7), Niemann-Pick disease (272.7), sphingolipidosis (272.7)
  • 330.0 Leukodystrophy
  • 272.7 Lipidoses (Fabry Disease)
  • 272.2 Mixed hyperlipidemia, Broad- or floating-betalipoproteinemia, Combined hyperlipidemia, Elevated cholesterol with elevated triglycerides NEC, Fredrickson Type IIb or III hyperlipoproteinemia, Hypercholesterolemia with endogenous hyperglyceridemia, Hyperbetalipoproteinemia with prebetalipoproteinemia, Tubo-eruptive xanthoma Xanthoma tuberosum
For price inquiries please email

**The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.


  1. Diaz-Font et al., (2005) Hum Genet 117:275- 277.
  2. Henseler et al., (1996) Am J Hum Genet 58:65-74.
  3. Kretz et al., (1990) Proc Natl Acad Sci 87:2541-2544.
  4. Regis et al., (1999) Eur J Hum Genet 7:125-130.
  5. Wrobe et al., (2000) J Inherit Metab Dis 23:64-76.
  6. Tylki-Szymanska et al., (2007) Clin Genet 72:538-542.
  7. Hulkova et al., (2001) Hum Mol Genet 10:927-940.
  8. Kuchar et al., (2009) Am J Med Genet A 149A:613-21.
  9. Schnabel et al., (1992) J Biol Chem 267:3312-5.
  10. Spiegel et al., (2005) Mol Genet Metab 84:160-166.
  11. Zuhair et al., (2009) J Child Neurol 24:1513-1519.
  12. Vaccaro et al., (2010) Hum Mol Genet 19:2987-2997.
  13. Fernandes J. (2006). Inborn Metabolic Diseases. Heidelberg, Germany: Springer Medizin Verlag.